- Research article
- Open Access
Enhanced transduction of colonic cell lines in vitroand the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin
© Farlow et al; licensee BioMed Central Ltd. 2007
- Received: 01 June 2007
- Accepted: 28 November 2007
- Published: 28 November 2007
Virus-mediated delivery of therapeutic transgenes to the inflamed colon holds a great potential to serve as an effective therapeutic strategy for inflammatory bowel disease, since local, long-term expression of the encoded therapeutic proteins in the colorectal system is potentially achievable. Viral vectors, derived from adeno-associated virus (AAV), should be very useful for such therapeutic strategies, particularly because they can establish long-term expression of transgenes. However, few studies have been carried out to investigate the ability of AAV-based vectors to transduce the inflamed colon.
AAV, derived from adeno-associated virus serotype 2 (AAV2), showed a limited ability to transduce colonic cell lines in vitro when used in free form. No appreciable enhancement of the transduction efficiency was seen when AAV2 particles were attached stably to the surfaces of microbeads and delivered to target cells in the form of AAV2-microbead conjugates. However, the transduction efficiency of these colonic cell lines was enhanced substantially when a lectin, concanavalin A (Con A), was co-attached to the microbead surfaces, to which AAV2 particles had been conjugated. This considerable infectivity enhancement of AAV2-microbead conjugates by the co-attachment of Con A may be derived from the fact that Con A binds to α-D-mannosyl moieties that are commonly and abundantly present in cell-surface carbohydrate chains, allowing the conjugates to associate stably with target cells. Intracolonical administration of free AAV2 or AAV2-microbead conjugates without Con A into a mouse colitis model by enema showed very poor transduction of the colonic tissue. In contrast, the delivery of AAV2 in the form of AAV2-microbead conjugates bearing Con A resulted in efficient transduction of the inflamed colon.
AAV2-microbead conjugates bearing Con A can serve as efficient gene transfer agents both for poorly permissive colonic cell lines in vitro and for the inflamed colon in a mouse colitis model. This efficient transduction system for the inflamed colon should be useful for the development of gene therapy strategies for inflammatory bowel disease.
- Inflammatory Bowel Disease
- Colonic Tissue
- Efficient Transduction
- Colonic Cell Line
- Inflame Colon
Inflammatory bowel disease (IBD), consisting of two idiopathic inflammatory disorders, Crohn's disease and ulcerative colitis, is characterized by chronic intestinal inflammation, which causes severe destruction of the mucosa of the colorectal system [1–4]. An intense, local immune response is like to be responsible for the initiation and progress of the inflammatory process. A variety of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-2, IL-12, and interferon-γ, are involved in these inflammatory processes. Thus, one potential therapeutic strategy for IBD is to repress these inflammatory processes by using anti-inflammatory cytokines, extracellular domains of the receptors of pro-inflammatory cytokines, and antagonists and antibodies against pro-inflammatory cytokines. Gene therapy approaches are particularly attractive for such therapeutic strategies, since local, long-term expression of therapeutic proteins in the colorectal system is potentially achievable. Previous studies primarily used adenoviral vectors (Ad5), derived from adenovirus serotype 5, as gene transfer agents for the inflamed colon. Although the colorectal system is readily accessible externally, the presence of the mucous coat on the colonic epithelium and the dynamic fluidic properties of the colorectal system act as barriers for the access to the colonic tissue by viral vectors that are administered intracolonically. Thus, administration of relatively large amounts of Ad5 was required to achieve sufficient levels of transgene expression in the colon [5–7]. We recently showed by using Ad5 with a mouse chemically induced colitis model that the transduction efficiency of the inflamed colon by Ad5 was very poor when administered intracolonically in free form, but that it was enhanced considerably when Ad5 was used in the form of Ad5-microbead conjugates bearing a lectin, concanavalin A (Con A), which serves as an effective anchoring agent for the conjugates . When an Ad5 construct carrying the gene for mouse IL-10, a potent anti-inflammatory cytokine that is among the most promising protein therapeutics for IBD [9–19], was administered intracolonically in the form of Ad5-microbead conjugates bearing Con A, a considerable increase in the local IL-10 level in the colon was seen. This suggests that intracolonical administration of viral vectors carrying the genes for IL-10 and other therapeutic proteins may serve as an effective therapeutic strategy for IBD. However, the use of Ad5 for gene therapy of IBD may be limited to short-term therapeutic strategies, since commonly used Ad5 constructs are incapable of establishing long-term expression of transgenes and induce immune responses to transduced cells due to the expression of viral genes that are also present in the viral genome. Viral vector species that can provide sustained expression of therapeutic transgenes may be more useful for long-term therapy of IBD.
Adeno-associated viral vectors (AAV) are among the most frequently used viral vector species for in vivo gene therapy applications [20–25]. AAV, derived from adeno-associated virus serotype 2 (AAV2), has primarily been used, and extensive effort is being made to modify or engineer its properties, such as the infectivity and tropism. Recent studies are also focused on the development and characterization of AAV constructs that are derived from other serotypes and variants. AAV possesses several attractive characteristics as in vivo gene transfer agents: AAV is associated with no known pathogenesis, does not stimulate cell-mediated immune responses, has the ability to transduce a wide range of cell types (i.e., broad tropism), and has the ability to establish long-term expression of transgenes. These multiple attractive properties, particularly its ability to provide sustained expression of transgenes, suggest that AAV may serve as a useful viral vector species for the development of gene therapy strategies for IBD. However, to our knowledge, AAV-based vectors were not previously tested for the transduction of the inflamed colon.
In the present work, we investigated if AAV2 could be used for efficient transduction of the inflamed colon in mice toward its application to gene therapy of IBD. AAV2, when used in free form, showed a limited ability to transduce colonic cell lines in vitro. In addition, the transduction efficiency of the inflamed colon in a mouse colitis model was very poor when free AAV2 was administered intracolonically by enema. Thus, we examined if the transduction efficiencies of colonic cell lines and the inflamed colon in mice could be enhanced by the delivery of AAV2 in the form of virus-microbead conjugates bearing lectin as an anchoring agent.
We initially investigated, by using in vitro systems, the infectivity of AAV2 for two colonic cell lines, COLO 205 (human colorectal adenocarcinoma) and MIP-101 (human colorectal carcinoma), along with the human cervical adenocarcinoma cell line HeLa, which is known to be highly permissive to infection by AAV2. We used an AAV2 construct, AAV2.CMV-LacZ, which carries the bacterial lacZ (β-galactosidase) gene under the control of the human cytomegalovirus immediate/early promoter. The infectivity of AAV2.CMV-LacZ in free form for these two colonic cell lines was lower by one to two orders of magnitude than that for HeLa cells (data not shown), suggesting that colonic cells may be poorly permissive to infection by AAV2. This result prompted us to investigate if the delivery of AAV2 to target cells in the form of virus-microbead conjugates could enhance the transduction efficiency of colonic cells.
We previously showed with Ad5-microbead conjugates [8, 27] that the co-attachment of a lectin, Con A, to the microbead surface allowed the conjugates to associate stably with target cells due to the ability of Con A to bind to commonly occurring α-D-mannosyl moieties in cell-surface carbohydrate chains, resulting in efficient transduction of the target cells. We assessed if the ability of AAV2-microbead conjugates to associate with target cells and subsequently transduce them could also be enhanced by the co-attachment of lectins on the microbead surfaces. AAV2-microbead conjugates were prepared as above (9.2 AAV2 particles per microbead), and then biotinylated forms of several lectins with different carbohydrate specificities (see the Methods section) were co-attached to the microbead surfaces. These conjugates were analyzed for their infectivity on HeLa, COLO 205, and MIP-101 cells (Fig. 2). For HeLa cells, which are highly permissive to infection by free AAV2, the co-attachment of lectins to the microbead surface showed little effect on the infectivity of AAV2-microbead conjugates (p > 0.05 for all of the lectins used). In contrast, the infectivity of AAV2-microbead conjugates on COLO 205 and MIP-101 cells was enhanced considerably when certain lectins were co-attached to the microbead surfaces. In particular, the co-attachment of Con A showed dramatic enhancement of the infectivity of AAV2-microbead conjugates for these colonic cell lines (p < 0.01 for both COLO 205 and MIP-101). When COLO 205 cells were used as targets, the infectivity of AAV2-microbead conjugates bearing Con A became approximately 30-fold higher than those of free, unmodified AAV2 or AAV2-microbead conjugates without lectin (p < 0.01). Similarly, the co-attachment of Con A enhanced the infectivity of AAV2-microbead conjugates for MIP-101 cells by approximately 4-fold, as compared to free, unmodified AAV2 or AAV2-microbead conjugates without lectin (p < 0.01). No appreciable effect on the morphology and viability of target cells was seen for any of these cell lines when Con A was co-attached to the microbead surfaces. Other lectins tested showed little effect on the infectivity of AAV2-microbead conjugates on COLO 205 and MIP-101 cells, except for castor bean agglutinin I that enhanced the infectivity of the conjugates for COLO 205 cells by approximately 8-fold (p < 0.01). The considerable infectivity enhancement of AAV2-microbead conjugates by the co-attachment of Con A for these poorly permissive colonic cell lines may be derived from the fact that Con A binds to α-D-mannosyl moieties that are commonly and abundantly present in cell-surface carbohydrate chains, allowing the conjugates to associate with target cells with much higher efficiencies.
In the present study, we have demonstrated that AAV2-microbead conjugates bearing Con A can serve as efficient gene transfer agents both for colonic cell lines in vitro and for the inflamed colon in a mouse colitis model. Con A was found to be an effective anchoring agent for AAV2-microbead conjugates, providing efficient transduction of target cells and tissues both in vitro and in vivo. The infectivity enhancement by the co-attachment of Con A is likely derived from the ability of Con A on the microbead surfaces to allow the conjugates to associate stably with target cells or tissues due to its ability to bind to commonly occurring α-D-mannosyl moieties in cell-surface carbohydrate chains. The ability to associate stably with target tissue may be particularly important for the transduction of the colorectal system, where the dynamic fluidic properties inhibit stable association of viral particles with colonic tissues. We also analyzed the transduction of the normal colons (i.e., without colonic inflammation) in mice by AAV2 upon intracolonical administration. Under the conditions used for the transduction of the colons with TNBS-induced colitis (Fig. 4), no appreciable transduction of the normal colons was seen when AAV2 was used either in free form or in the form of AAV2-microbead conjugates with or without the co-attachment of Con A (data not shown). These results suggest that the exposure of colonic tissue by the destruction of the mucous coat on the colonic epithelium upon the development of TNBS-induced colitis is critical for AAV-microbead conjugates bearing Con A to associate stably to the colonic tissue and subsequently transduce colonic cells.
A different strategy for the construction of AAV2-microbead conjugates was previously reported . In this strategy, microbeads are coated with the primary receptor of AAV2, heparan sulfate, to which unmodified AAV2 particles are attached. We tested this strategy in vitro by using avidin-coated microbeads with physiological specific gravity, used in this study, with unmodified AAV2.CMV-LacZ. No appreciable enhancement of the infectivity was seen with these AAV2-microbead conjugates, as compared to free AAV2.CMV-LacZ, when analyzed using cultured colonic cell lines (data not shown). This may be derived from the physiological specific gravity of such conjugates, with which their ability to associate with target cells may be similar to that of free AAV2, as seen with AAV2-microbead conjugates without lectin in this study. The presence of large amounts of heparan sulfate on the microbead surfaces may also inhibit efficient binding of attached AAV2 particles to cell-surface heparan sulfate. In addition, this strategy does not allow the co-attachment of other materials on the microbead surfaces, to which AAV2 particles have been conjugated. Thus, the use of such conjugates for the transduction of the inflamed colon may be limited, since their association with colonic tissue upon intracolonical administration should be inefficient without the co-attachment of an appropriate anchoring agent, such as Con A. In contrast, a key strength of our strategy is that almost any materials can readily be co-attached to the microbead surfaces, to which AAV2 particles (or other viral particles used) have been conjugated. This should allow the properties and functionality of AAV2-microbead conjugates to be controlled or engineered in a systematic manner. In addition, our strategy should be applicable to AAV-based vectors that are derived from not only AAV2 but also other serotypes and variants. This should make our strategy applicable to the transduction of a wide range of cell types and tissue targets.
This study has demonstrated that the delivery of AAV2 in the form of AAV2-microbead conjugates bearing the lectin Con A provides considerable enhancements of the transduction efficiency both for poorly permissive colonic cell lines in vitro and for the inflamed colon in mice upon intracolonical administration by enema. In particular, the co-attachment of Con A to the microbead surfaces as an anchoring agent was found essential for efficient transduction of colonic cells by AAV2-microbead conjugates both in vitro and in vivo. With this efficient AAV2-mediated transduction system for the inflamed colon, it should now be possible to investigate, systematically, the efficacy of potential gene therapy strategies for IBD by using the genes for a variety of different protein therapeutics. Such protein therapeutics should include the anti-inflammatory cytokine IL-10, antibodies against the pro-inflammatory cytokine TNF-α, and the extracellular domain of the TNF-α receptor, each of which has shown potential effectiveness for the therapy of IBD.
An AAV2 construct, AAV2.CMV-LacZ, was obtained from the Vector Core, Harvard Gene Therapy Initiative, Dana-Farber/Harvard Cancer Center, Boston, MA. AAV2.CMV-LacZ, derived from adeno-associated virus serotype 2, carries the bacterial lacZ (β-galactosidase) gene with a nuclear localization signal under the control of the human cytomegalovirus immediate/early promoter with the polyadenylation signal of the bovine growth hormone gene. Prior to use, AAV2.CMV-LacZ was purified twice by affinity chromatography using heparin as the ligand  (heparin-agarose type I; Sigma).
The following four human cell lines were used as targets for in vitro experiments: HeLa (cervical adenocarcinoma), COLO 205 (colorectal adenocarcinoma), MIP-101 (colorectal carcinoma), and SW620 (colorectal adenocarcinoma). HeLa, COLO 205, and SW620 were obtained from the American Type Culture Collection (Manassas, VA), and MIP-101 was a generous gift from Peter Thomas, Boston University School of Medicine, Boston, MA. HeLa and SW620 cells were maintained in Dulbecco's modified Eagle's medium (BioWhittaker), supplemented with 10% fetal bovine serum (BioWhittaker). COLO 205 and MIP-101 cells were maintained in RPMI 1640 medium (BioWhittaker), supplemented with 10% fetal bovine serum, 4.5 mg/ml glucose, 1.5 mg/ml sodium bicarbonate, and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
Biotinylation of AAV2 particles
A water-soluble, amino-reactive biotinylation reagent, sulfo-NHS-LC-biotin (Pierce) [8, 26, 27, 32], was used to biotinylate AAV2 particles. Sulfo-NHS-LC-biotin was freshly dissolved in Dulbecco's phosphate-buffered saline (PBS) containing 0.05% Tween 20 (PBST) and added to AAV2.CMV-LacZ in PBST (1 × 1010 AAV2 particles/ml) at varying final concentrations (0 – 2 mg/ml). The mixtures were incubated at room temperature (~22°C) for 45 min in the dark, and the biotinylation reaction was terminated by the addition of glycine in PBS to a final concentration of 10 mM. The resulting biotinylated AAV2 particles were analyzed for their infectivity by using HeLa cells as the targets. HeLa cells were grown in 24-well plates (5 × 104 cells per well) at 37°C for 24 hr. Then, each biotinylated AAV2.CMV-LacZ preparation was applied to target cells (5 × 106 AAV2 particles per well containing 500 μl of culture media) and incubated at 37°C for 48 hr. Cells were fixed with 0.5% glutaraldehyde and stained for β-galactosidase (LacZ) activity using X-gal as the substrate. The numbers of infected, lacZ-expressing cells were counted under a light microscope. The same analysis was also performed by using biotinylated AAV2.CMV-LacZ preparations, to which excess amounts of Neutralite avidin (Southern Biotechnology Associates) (100 μg per 5 × 106 AAV2 particles) had been added, to assess the biotinylation of the viral surfaces.
Preparation of AAV2-microbead conjugates with and without the co-attachment of lectin
Preparation of AAV2-microbead conjugates was carried out by using AAV2.CMV-LacZ and avidin-coated fluorescent polystyrene microbeads (diameter, 480 nm; specific gravity, 1.06 g/cm3) (Spherotech), in which a rhodamine derivative (red fluorescence) is encapsulated. AAV2.CMV-LacZ was biotinylated with sulfo-NHS-LC-biotin at 50 μg/ml as above. After the termination of biotinylation reaction by the addition of glycine, biotinylated AAV2 particles were dialyzed against PBST to remove non-virion-associated biotinylation reagent. Dialyzed AAV2 particles were mixed with avidin-coated microbeads at appropriate ratios. The mixtures were incubated at room temperature for 30 min with occasional mixing, followed by the removal of unbound AAV2 particles by centrifugation. The supernatant fraction, which contained unbound AAV2 particles, was analyzed for its infectivity on HeLa cells to determine the number of bound AAV2 particles per microbead.
The following lectins in biotinylated form were obtained from Vector Laboratories [the carbohydrate structure(s), to which each lectin binds, is indicated in bracket]: Con A from Jack bean (Canavalia ensiformis) seeds [mannose]; agglutinin from horse gram (Dolichos biflorus) seeds [N-acetylgalactosamine]; agglutinin from peanuts (Arachis hypogaea) [galactosyl (β-1,3)N-acetylgalactosamine]; agglutinin I from castor bean (Ricinus communis) seeds [galactose and N-acetylglucosamine]; agglutinin from soybean (Glycine max) seeds [N-acetylgalactosamine and galactose]; agglutinin I from furze gorse (Ulex europaeus) seeds [fucose]; and agglutinin from wheat germ (Triticum vulgaris) [N-acetylglucosamine]. The co-attachment of a lectin to the microbead surface was carried out by the addition of an excess amount of a biotinylated form of the lectin to AAV2-microbead conjugates (0.2 μg biotinylated lectin per 107 avidin-coated microbeads), followed by the removal of unbound lectin molecules by centrifugation.
Infectivity analysis of AAV2-microbead conjugates with and without lectin
The infectivity of AAV2-microbead conjugates with and without the co-attachment of lectin, prepared above, was analyzed by using HeLa, COLO 205, MIP-101, and SW620 cell lines as targets. Cells were cultured in 24-well plates at 37°C for 24 hr. AAV2-microbead conjugates with and without lectins, along with free, unmodified AAV2.CMV-LacZ and free, biotinylated AAV2.CMV-LacZ as controls, were applied to each well. The actual numbers of target cells and AAV2 particles per well for each cell line are given in the legends to Figs. 2 and 3. Cells were incubated at 37°C for 48 hr, fixed with glutaraldehyde, and stained for β-galactosidase activity using X-gal as the substrate. Then, the numbers of infected cells were counted under a light microscope.
In vivotransduction of the inflamed colon in mice by AAV2-microbead conjugates
All animal procedures were carried out in accordance with NIH guidelines following approval by the Harvard Medical Area Standing Committee on Animals. A mouse acute colitis model was prepared by intracolonical administration of TNBS (Sigma) (0.75 mg in 100 μl of 50% ethanol per mouse) into Balb/c mice (6 – 8 weeks old; Taconic) by enema, as described previously . These mice with TNBS-induced colitis were subjected to experimentation at 48-hr post-administration of TNBS, at which time severe destruction of the mucosal layer was seen in the colon and the mice lost their weight by 10 – 15% during the 48-hr period. AAV2-microbead conjugates bearing Con A were prepared by using AAV2.CMV-LacZ at 32 AAV2 particles per microbead, as described above. These conjugates were administered intracolonically into mice with TNBS-induced colitis by enema (a total of 1 × 1010 AAV2 particles in 100 μl PBST per mouse). As controls, free, unmodified AAV2.CMV-LacZ and AAV2-microbead conjugates without Con A were administered into mice with TNBS-induced colitis in the same manner. At 48-hr post-administration, mice were euthanized, and their colons were collected. These colons samples were frozen in tissue freezing media (Tissue-Tek O.C.T. compound, Miles), followed by the preparation of cryosections (thickness, 5 – 7 μm). Colon sections were stained for β-galactosidase activity using X-gal as the substrate, with counter-staining with eosin/phloxine B. Stained colon sections were examined under a light microscope (Axioscop 2, Carl Zeiss).
When the spatial relationship between transductions sites and the location of tissue-associated microbeads was analyzed, colon sections were stained for β-galactosidase activity using X-gal as the substrate. Stained colon sections (without counter-staining) were initially examined under a fluorescence microscope (Axioscop 2) to detect tissue-associated microbeads (red fluorescence). Then, the colon sections were counter-stained with eosin/phloxine B and examined under a light microscope (Axioscop 2) for the detection of transduction sites, where images at the same location as fluorescence detection of tissue-associated microbeads above were captured.
We thank Dr. Peter Thomas for providing the MIP-101 cell line and Dr. Roderick Bronson for histological analysis. AJ was supported by a training grant from the National Institutes of Health (CA59367; Principal Investigator, Dr. Melvin E. Clouse). This work was supported, in part, by a grant from the National Institutes of Health (EB03012).
- Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002, 20: 495-549. 10.1146/annurev.immunol.20.100301.064816.View ArticleGoogle Scholar
- Podolsky DK: Inflammatory bowel disease. N Engl J Med. 2002, 347: 417-429. 10.1056/NEJMra020831.View ArticleGoogle Scholar
- Bouma G, Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003, 3: 521-533. 10.1038/nri1132.View ArticleGoogle Scholar
- Korzenik JR, Podolsky DK: Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov. 2006, 5: 197-209. 10.1038/nrd1986.View ArticleGoogle Scholar
- Wirtz S, Galle PR, Neurath MF: Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut. 1999, 44: 800-807.View ArticleGoogle Scholar
- Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF: Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol. 2002, 168: 411-420.View ArticleGoogle Scholar
- Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ: Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut. 2003, 52: 981-987. 10.1136/gut.52.7.981.View ArticleGoogle Scholar
- Jerusalmi A, Farlow SJ, Sano T: Use of lectin as an anchoring agent for adenovirus-microbead conjugates: Application to the transduction of the inflamed colon in mice. Gene Ther Mol Biol. 2006, 10: 223-232.Google Scholar
- Izcue A, Coombes JL, Powrie F: Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006, 212: 256-271. 10.1111/j.0105-2896.2006.00423.x.View ArticleGoogle Scholar
- Kurtovic J, Segal I: Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol. 2004, 25: 9-14.Google Scholar
- Li MC, He SH: IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol. 2004, 10: 620-625.View ArticleGoogle Scholar
- Stokkers PC, Hommes DW: New cytokine therapeutics for inflammatory bowel disease. Cytokine. 2004, 28: 167-173. 10.1016/j.cyto.2004.07.012.View ArticleGoogle Scholar
- Wirtz S, Neurath MF: Inflammatory bowel disorders: gene therapy solutions. Curr Opin Mol Ther. 2003, 5: 495-502.Google Scholar
- Braat H, Peppelenbosch MP, Hommes DW: Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin Biol Ther. 2003, 3: 725-731. 10.1517/14712522.214.171.1245.View ArticleGoogle Scholar
- Asadullah K, Sterry W, Volk HD: Interleukin-10 therapy - review of a new approach. Pharmacol Rev. 2003, 55: 241-269. 10.1124/pr.55.2.4.View ArticleGoogle Scholar
- Wirtz S, Neurath MF: Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther. 2003, 10: 854-860. 10.1038/sj.gt.3302013.View ArticleGoogle Scholar
- Ogata H, Hibi T: Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des. 2003, 9: 1107-1113. 10.2174/1381612033455035.View ArticleGoogle Scholar
- Veljaca M: Anti-inflammatory peptides and proteins in inflammatory bowel disease. Curr Opin Investig Drugs. 2001, 2: 1387-1394.Google Scholar
- Sandborn WJ: Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis. 2001, 7 Suppl 1: S9-16. 10.1002/ibd.3780070504.View ArticleGoogle Scholar
- McCarty DM, Young SM, Samulski RJ: Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004, 38: 819-845. 10.1146/annurev.genet.37.110801.143717.View ArticleGoogle Scholar
- Carter BJ: Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol Ther. 2004, 10: 981-989. 10.1016/j.ymthe.2004.09.011.View ArticleGoogle Scholar
- Flotte TR: Adeno-associated virus-based gene therapy for inherited disorders. Pediatr Res. 2005, 58: 1143-1147. 10.1203/01.pdr.0000189226.03684.fe.View ArticleGoogle Scholar
- Li C, Bowles DE, van Dyke T, Samulski RJ: Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005, 12: 913-925. 10.1038/sj.cgt.7700876.View ArticleGoogle Scholar
- Wu Z, Asokan A, Samulski RJ: Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006, 14: 316-327. 10.1016/j.ymthe.2006.05.009.View ArticleGoogle Scholar
- Warrington KH, Herzog RW: Treatment of human disease by adeno-associated viral gene transfer. Hum Genet. 2006, 119: 571-603. 10.1007/s00439-006-0165-6.View ArticleGoogle Scholar
- Pandori M, Hobson D, Sano T: Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery. Virology. 2002, 299: 204-212. 10.1006/viro.2002.1510.View ArticleGoogle Scholar
- Pandori MW, Sano T: Chemically inactivated adenoviral vectors that can efficiently transduce target cells when delivered in the form of virus-microbead conjugates. Gene Ther. 2005, 12: 521-533. 10.1038/sj.gt.3302420.View ArticleGoogle Scholar
- Green NM: Avidin. Adv Protein Chem. 1970, 29: 85-133.View ArticleGoogle Scholar
- Green NM: Avidin and streptavidin. Methods Enzymol. 1990, 184: 51-67.View ArticleGoogle Scholar
- Sano T, Vajda S, Reznik GO, Smith CL, Cantor CR: Molecular engineering of streptavidin. Ann N Y Acad Sci. 1996, 799: 383-390. 10.1111/j.1749-6632.1996.tb33229.x.View ArticleGoogle Scholar
- Wilchek M, Bayer EA: Foreword and introduction to the book (strept)avidin-biotin system. Biomol Eng. 1999, 16: 1-4. 10.1016/S1050-3862(99)00032-7.View ArticleGoogle Scholar
- Hobson DA, Pandori MW, Sano T: In situ transduction of target cells on solid surfaces by immobilized viral vectors. BMC Biotechnol. 2003, 3: 4-10.1186/1472-6750-3-4.View ArticleGoogle Scholar
- Jurjus AR, Khoury NN, Reimund JM: Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004, 50: 81-92. 10.1016/j.vascn.2003.12.002.View ArticleGoogle Scholar
- Mah C, Fraites TJ, Zolotukhin I, Song S, Flotte TR, Dobson J, Batich C, Byrne BJ: Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther. 2002, 6: 106-112. 10.1006/mthe.2001.0636.View ArticleGoogle Scholar
- Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N: Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6: 973-985. 10.1038/sj.gt.3300938.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.